Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CyFi2: Ficlatuzumab + HiDAC in AML
NCT04100330Phase 2Withdrawn
- Sponsor
- AVEO Oncology
- Start
- Jan 2020
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of ficlatuzumab in acute myeloid leukemia (AML) (2 arms), sponsored by AVEO Oncology. Primary endpoint: Overall Response Rate at 13 months. Planned start Jan 2020; status: withdrawn.
02
Drugs
ficlatuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04100330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04100330.